Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia - Who might benefit?

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Very preterm infants are susceptible to bronchopulmonary dysplasia (BPD), a leading cause of mortality and long-term morbidity.
• Postnatal corticosteroids are considered for BPD prevention and treatment, but potential neurodevelopmental risks necessitate careful consideration.
• Optimal timing and delivery of corticosteroids are critical to maximize benefits and minimize harm.

Purpose of the Study:

• To evaluate the efficacy and safety of postnatal corticosteroids in preventing or reducing the severity of bronchopulmonary dysplasia in very preterm infants.
• To compare the effects of systemic versus inhaled corticosteroids and assess the impact of administration timing.
• To explore novel delivery methods like intratracheal instillation for targeted lung delivery.

Main Methods:

• Review of existing literature on postnatal corticosteroid use in very preterm infants.
• Analysis of studies stratifying corticosteroid effects based on timing of initiation (first week vs. after first week).
• Comparison of outcomes associated with systemic, inhaled, and intratracheal corticosteroid administration.

Main Results:

• Systemic corticosteroids initiated after the first week of life demonstrate the most benefit for infants at high risk of BPD.
• Inhaled corticosteroids show limited efficacy in established lung disease.
• Early systemic corticosteroids (within the first week) are not recommended due to potential adverse effects.
• Intratracheal corticosteroids, delivered via surfactant, show promise for BPD prevention.

Conclusions:

• Systemic corticosteroids administered after the first postnatal week are beneficial for high-risk very preterm infants to prevent or reduce BPD severity.
• Inhaled corticosteroids are less effective for established lung disease.
• Intratracheal corticosteroid delivery presents a promising strategy for BPD prevention, potentially minimizing systemic exposure and neurodevelopmental risks.